Anti-amyloid Monoclonal Antibodies in Alzheimer’s Disease: A New Hope

Abstract

Objectives: The current review aimed to collect the updated clinical investigations of monoclonal antibodies (mAbs) in Alzheimer’s disease (AD) patients and assess the feasibility and efficacy of the immunotherapies with mAbs in AD. Design: A narrative review. Participants: People with AD. Outcome measures: The occurrence of AD. Results: The failure of all attempts to cure AD during the previous decades by focusing on the pathogenic factors revealed that the pathophysiology of AD is multifaceted. In recent years, anti-amyloid mAbs that exhibit beneficial effects in AD treatment have been marketed, and different studies have attempted to assess their effects. We investigated the current research to determine the potential benefits and outcomes of clinical trials of mAbs in AD cases in the review. Conclusions: This study concentrated on determining how these drugs affect AD pathology. It offers potential support for using anti-amyloid mAb immunotherapy for AD and evaluates the lessons learned from these clinical studies to conduct further research on the beneficial and harmful impacts of these therapeutic agents.